drugset / Trial / NCT03571568
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Timeline
- Start
- 2018-05-16
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | BI-1206 | Monoclonal antibody | 50 mg | Subcutaneous |
| Subject | BI-1206 | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | BI-1206 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | BI-1206 | Monoclonal antibody | 225 mg | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |